Certolizumab Pegol in Plaque Psoriasis: Considerations for Pregnancy.
Certolizumab Pegol in Plaque Psoriasis: Considerations for Pregnancy.
复制标题
Certolizumab Pegol 治疗斑块型银屑病：妊娠注意事项。
作者：
Jeremy F. Strain;Maria Leis;Kyle Lee;P. Fleming
牛皮癣是一种慢性、免疫介导的皮肤病，通常影响育龄妇女。Certolizumab pegol （CZP）是一种抗肿瘤坏死因子- α (anti- tnf - α)药物，在治疗中度至重度斑块性银屑病方面已被证明具有长期安全性和有效性。此前，关于其在妊娠期使用的安全性数据有限。本文的目的是回顾CZP的关键临床试验数据，并探讨该药物在妊娠期的安全性考虑。本综述表明，基于药代动力学和现有的安全性数据，CZP为育龄妇女提供了一种安全有效的治疗选择。观察到的主要先天性畸形和流产的发生率似乎并不高于一般人群中这些的背景发生率，根据其已知的安全性，对母亲的风险是最小的。应考虑使用CZP治疗斑块型银屑病，并与考虑生育或正在怀孕或哺乳的患者进行讨论。
Psoriasis is a chronic, immune-mediated skin condition which commonly affects women of childbearing age. Certolizumab pegol (CZP) is an anti-tumor necrosis factor-alpha (anti-TNFα) agent that has demonstrated long-term safety and efficacy in treating moderate-to-severe plaque psoriasis. Previously, there has been limited safety data surrounding its use in pregnancy. The objective of this article is to review pivotal clinical trial data for CZP and explore safety considerations for this agent in pregnancy. This review demonstrates that CZP offers a safe and effective treatment option for women during childbearing years based on pharmacokinetics and available safety data. The observed occurrence of major congenital malformations and miscarriages appears to be no greater than the background occurrence of those in the general population, and risks to the mother are minimal based on its known safety profile. The use of CZP for treatment of plaque psoriasis should be considered and discussed with patients considering childbearing or whom are currently pregnant or breastfeeding.